Nicholas Hill, MD
Pulmonary Disease · Boston, MANPI 1558308874
Payments from drug & device makers
Across 408 payments — averaging $1900.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$307K
- Sanofi$141K
- Fisher & Paykel Healthcare Limited$59K
- Insmed, Inc.$57K
- Sumitomo Pharma America, Inc.$55K
- Boehringer Ingelheim$37K
- plus $120K from 23 others
Across 4 payments — averaging $297.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Insmed, Inc.$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 130 | $306,779 |
| Sanofi | 106 | $140,724 |
| Fisher & Paykel Healthcare Limited | 7 | $59,449 |
| Insmed, Inc. | 15 | $57,147 |
| Sumitomo Pharma America, Inc. | 7 | $54,736 |
| Boehringer Ingelheim | 19 | $37,052 |
| Novartis | 4 | $29,368 |
| Genentech USA, Inc. | 19 | $26,162 |
| Merck | 19 | $12,452 |
| Philips North America LLC | 3 | $11,338 |
| Fisher & Paykel Healthcare Inc | 14 | $8,866 |
| Breas Medical, Inc. | 4 | $6,875 |
| GSK | 7 | $5,069 |
| Inogen, Inc. | 3 | $4,050 |
| Livanova USA, Inc. | 2 | $3,410 |
| Actelion Pharmaceuticals, Ltd | 1 | $3,372 |
| CSL Behring | 1 | $3,254 |
| Upjohn US 1 LLC | 1 | $3,000 |
| Actelion Pharmaceuticals US, Inc. | 29 | $1,517 |
| Vapotherm Inc | 1 | $350 |
| Abbott | 1 | $162 |
| AstraZeneca | 5 | $111 |
| Sandoz | 2 | $95 |
| Johnson & Johnson(2 entities) | 3 | $76 |
| Bayer | 1 | $52 |
| Paratek Pharmaceuticals, Inc. | 1 | $40 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Aero US Inc | 1 | $31 |
| Liquidia Technologies, Inc. | 1 | $25 |
How this compares
$775,595 in reported general payments places this provider in the 95th percentile of 482 pulmonary disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Boston
- Aaron WaxmanBoston$7.7M
- John BerkBoston$6M
- Darrell KottonBoston$5.3M
- Hilary GoldbergBoston$3.5M
- Harrison FarberBoston$2.6M
- Elizabeth KlingsBoston$2.1M
- Gary HunninghakeBoston$1.5M
- Peter LacameraBoston$1.3M
- Barry SheaBoston$1M
- Isabel NeuringerBoston$817K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.